Sep. 22, 2011 UCLA researchers demonstrated that an over-the-counter dietary supplement may help inhibit development of insulin resistance and glucose intolerance, conditions that are involved in the development of Type 2 diabetes and metabolic syndrome, which affect millions worldwide.
In this early preclinical study, a naturally produced amino acid-like molecule called GABA was given orally to mice that were obese, insulin resistant and in the early stages of Type 2 diabetes. Researchers found that GABA suppressed the inflammatory immune responses that are involved in the development of this condition.
According to study authors, GABA helped prevent disease progression and improved glucose tolerance and insulin sensitivity, even after onset of Type 2 diabetes in mice. Researchers also identified the regulatory immune cells that likely direct GABA's activity in inhibiting inflammation.
Researchers note that in the future, GABA taken as a supplement or related medications may provide new therapeutic agents for the treatment of obesity-related Type 2 diabetes and metabolic syndrome.
Other social bookmarking and sharing tools:
The above story is reprinted from materials provided by University of California - Los Angeles Health Sciences, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
- Jide Tian, Hoa Dang, Daniel L. Kaufman. Combining Antigen-Based Therapy with GABA Treatment Synergistically Prolongs Survival of Transplanted ß-Cells in Diabetic NOD Mice. PLoS ONE, 2011; 6 (9): e25337 DOI: 10.1371/journal.pone.0025337
Note: If no author is given, the source is cited instead.